|
1. Biologie
|
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
Wales 'behind' in technology to detect prostate cancer [BBC News]
|
|
|
|
|
|
The
Multiparametic MRI (mpMRI) scan, which is done before a biopsy, is able
to boost detection of prostate cancer. In England, an NHS trial is
under way to cut prostate cancer diagnosis times from six weeks to a
matter of days using the scan. But in Wales only three out of seven
Welsh health boards provide the scan, as it is not currently recommended
by the National Institute of Clinical Excellence (NICE).
|
|
|
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
5. Traitements
|
|
|
JAK Inhibitors Associated with Aggressive Lymphoma [ASH]
|
|
|
|
|
|
Though
not a cure, JAK inhibitors are very effective at providing symptom
relief, said study coauthor Heinz Gisslinger, MD, of the Medical
University of Vienna in Austria. “However, we started noticing sporadic
cases of lymphomas developing in patients being treated for
myeloproliferative neoplasms and wanted to know if this phenomenon was
connected to treatment.”
|
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
How many PD-1 and PD-L1 checkpoint inhibitors do we need? [Pipeline Review]
|
|
|
|
|
|
Analysis
of the PD-1 and PD-L1 checkpoint inhibitor pipeline revealed 41 unique
molecules in clinical development by pharmaceutical companies, of which
12% are bispecific molecules and 27% are only developed so far in less
regulated countries. Further 15 unique molecules are undergoing
IND-enabling studies or have already applied for clinical trial of which
40% are bispecific molecules.
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
Roche pays $2.4 billion for rest of cancer expert Foundation Medicine [Reuters]
|
|
|
|
|
|
It
is the latest in a series of bolt-on acquisitions by Roche as the
world’s largest marker of cancer drugs seeks to tap into promising
technology developed by biotech companies to drive future growth as its
older drugs face competition. Earlier this year it agreed to buy the
rest of U.S. cancer data company Flatiron Health for $1.9 billion in a
similar deal.
|
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.9.3 EHA
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.5 Médecines alternatives
|
|
|
ASCO endorses the integration of quackery into breast cancer care [Science-based Medicine]
|
|
|
|
|
|
In
2014, the Society for Integrative Oncology first published clinical
guidelines for the care of breast cancer patients. Not surprisingly, SIO
advocated “integrating” dubious therapies with oncology. Last week, the
most influential oncology society, the American Society of Clinical
Oncology (ASCO), endorsed a 2017 update to the SIO guidelines, thus
endorsing the “integration” of quackery with oncology and paving the way
for insurance coverage.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|